ReviewFrontiers in cell and developmental biology2025
Developments in the study of the role of lactate metabolism in the genesis and progression of thyroid cancer.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination.Cancer & metabolism · 2026Article
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Protein lactylation in Alzheimer's disease: bridging metabolism, pathology, and therapeutic opportunity.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid carcinoma is among the most common endocrine system malignancies. Lactate metabolism and lactylation modification roles in carcinogenesis and development have garnered more interest in recent years. The expression and function of lactate transporters (MCTs) and significant metabolic enzymes are included in our summary of the characterisation of lactate metabolism in thyroid cancer. We systematically dissect the multifaceted regulatory circuits governing lactate metabolism by integrating three pivotal dimensions: (i) canonical signaling cascades; (ii) tumor-microenvironmental variables, most notably hypoxia and acidosis; and (iii) the emerging epigenetic paradigm of lactylation, which dynamically reprograms the catalytic efficiency of rate-limiting enzymes and reshapes the transcriptional landscape of metabolic genes, thereby precisely coordinating lactate homeostasis. Furthermore, this review explains how lactate promotes thyroid cancer cell growth, invasion, metastasis, angiogenesis, and immunosuppression. It also discusses how lactate may contribute to treatment resistance. This paper provides new ideas for future research and clinical translation by summarizing the key findings and clinical significance of the current research on lactate metabolism in thyroid cancer, anticipating future research directions, and applying the development of more effective treatments that target lactate metabolism to clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.